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Abstract Lynch syndrome is one of the most common
hereditary colorectal cancer (CRC) syndrome and is caused
by germline mutations of MLH1, MSH2 and more rarely
MSH6, PMS2, MLH3 genes. Whereas the absence of MSH2
protein is predictive of Lynch syndrome, it is not the case
for the absence of MLH1 protein. The purpose of this study
was to develop a sensitive and cost effective algorithm to
select Lynch syndrome cases among patients with MLH1
immunohistochemical silencing. Eleven sporadic CRC and
16 Lynch syndrome cases with MLH1 protein abnor-
malities were selected. The BRAF c.1799T[ A mutation
(p.Val600Glu) was analyzed by direct sequencing after
PCR amplification of exon 15. Methylation of MLH1 pro-
moter was determined by Methylation-Sensitive Single-
Strand Conformation Analysis. In patients with Lynch
syndrome, there was no BRAF mutation and only one case
showed MLH1 methylation (6%). In sporadic CRC, all
cases were MLH1 methylated (100%) and 8 out of 11 cases
carried the above BRAF mutation (73%) whereas only 3
cases were BRAF wild type (27%). We propose the fol-
lowing algorithm: (1) no further molecular analysis should
be performed for CRC exhibiting MLH1 methylation and
BRAF mutation, and these cases should be considered as
sporadic CRC; (2) CRC with unmethylated MLH1 and
negative for BRAF mutation should be considered as Lynch
syndrome; and (3) only a small fraction of CRC with MLH1
promoter methylation but negative for BRAF mutation
should be true Lynch syndrome patients. These potentially
Lynch syndrome patients should be offered genetic coun-
selling before searching for MLH1 gene mutations.
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Lynch syndrome or hereditary nonpolyposis colorectal
cancer (HNPCC) syndrome is one of the most common
hereditary colon cancer syndrome, accounting for 3–6% of
the total colorectal cancer burden [1], and is caused by
germline mutations of mismatch repair (MMR) genes [2, 3].
MLH1 and MSH2 are the most commonly mutated MMR
genes in HNPCC, with mutations in MSH6 and PMS2 being
significantly less common and MLH3 mutations very rare
[3, 4]. Complete inactivation in any of the MMR genes
result in genomic instability, most evident within repeti-
tive mononucleotide or dinucleotide microsatellite DNA
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sequences which are particularly prone to replication errors
[5]. The resulting microsatellite instability (MSI) is widely
used as a prescreen in patients candidates for HNPCC
according to standardised methodology, and tumours with a
significant instability are referred to as MSI-high (MSI-H)
[6]. Nevertheless, approximately 10–15% of all sporadic
CRCs are also MSI-H, although these show no association
with HNPCC [7]. These common MSI-H sporadic tumours
do not result from a predisposing constitutive MMR gene
mutation, and typically show loss of expression of MLH1
protein consecutive to mono- or bi-allelic hypermethylation
of the gene promoter [8].
Sporadic MSI-H colorectal cancers and Lynch syn-
drome superficially resemble each other in that they are
frequently located in the proximal colon and share
morphological features such as mucin production and
tumour-infiltrating lymphocytes [9]. However, they have
been shown to differ in terms of demographics, molec-
ular alterations and natural history [10–12]. These two
subsets of MSI-H colorectal cancer need to be distin-
guished and investigated separately since the identifica-
tion of Lynch syndrome warrants specific management
policies with respect to genetic screening and surveil-
lance measures in both the patients and their first-degree
relatives.
The most effective strategy for the diagnosis of Lynch
syndrome is the compilation of a thorough family history
of colorectal cancer and fulfilment of the Amsterdam cri-
teria [13, 14]. However, this information is often not
available and about 20% of Lynch syndrome families with
germline mutations do not meet these criteria [15]. Current
laboratory testing algorithms for patients with suspected
Lynch syndrome typically include a prescreen step, in
which MSI testing and/or MMR protein immunohisto-
chemistry (IHC) are performed on tumour tissue prior to
more laborious and costly efforts aimed at identifying
mutations in the responsible MMR genes. Patients whose
tumours show loss of MSH2 expression almost invariably
have an underlying MSH2 or MSH6 germline mutation [16,
17]. As mentioned above MSI-H CRC cancers with loss of
MLH1 protein expression are more difficult to classify into
familial versus sporadic CRC categories because the
underlying germline MLH1 mutation or methylation of the
MLH1 gene promoter cannot be distinguished a priori.
Therefore, analysis of MLH1 promoter methylation status
can be a valuable mean to spare unnecessary genetic testing
in patients with sporadic MSI-H tumours [18, 19]. How-
ever, as our results strongly suggest, this strategy is not
sufficient because MLH1 promoter methylation is not
exclusive to sporadic CRC [20–24].
Recently, activating mutations in the BRAF protoonco-
gene have been associated with MSI-H tumours in general
[25], and subsequently with the sporadic subset in
particular, providing a further avenue for distinction
between familial and sporadic MSI-H tumours [26–29].
Here, we present the results of a comparative study
where we determined the methylation status of MLH1, and
the presence of BRAF mutations in both sporadic MSI-H
cancers with loss of expression of MLH1 protein, and
MLH1 mutated HNPCC patients. The aim of the study was
(1) to determine whether MLH1 methylation and BRAF
mutations might be used as negative predictors for HNPCC
in patients with MSI-H tumours, and (2) to design a cost




Sixteen patients with Lynch syndrome harbouring an
MLH1 constitutive mutation were selected from an anon-
ymised series investigated at the Institut Central des
Hoˆpitaux Valaisans in Sion, Switzerland. In addition, ele-
ven patients with sporadic MSI-H CRC and lacking of
MLH1 protein expression were selected from a previously
studied series after clinical genetic screening [19].
Immunohistochemistry
Immunohistochemical expression of MLH1 was investi-
gated as follows for each slide, dewaxed paraffin sections
were immunostained using the streptavidin–biotin peroxi-
dase complex method. Four micrometre thick tissue sec-
tions were mounted on aminopropylmethoxysilane-coated
glass slides, deparaffinized in xylol, taken through to
absolute alcohol, and blocked for endogenous peroxidase
with 1% hydrogen peroxide in methanol for 45 min. Slides
were then heated in a microwave oven for 15 min in
10 mM citrate buffer pH 6.0. To reduce nonspecific binding,
they were incubated in normal goat serum (Pel-Freez
Biologicals, Rogers, Arkansas) diluted 1:30 in TBS for
10 min. Sections were then incubated for 30 min with the
primary monoclonal antibodies for the gene products of
MLH1 (1:100, Pharmingen, Basel). Following the primary
antibody incubation, the sections were incubated for
30 min with goat anti-mouse IgG (Sternberger, Baltimore,
MD, USA) diluted 1:100 in NFDM/TBS, and with PAP-
complex diluted 1:600 in NFDM/TBS. Peroxidase activity
was revealed with 3,30-diaminobenzidine as the chromo-
gen, and the sections were counterstained with Mayer’s
acid-free hematoxylin. As a negative control, the mono-
clonal primary antibody was replaced by hybridoma
supernatant of a similar isotype but without reactivity in the
tissue examined.
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MSI analysis
For MSI analysis, microdissection was performed after
selection of tumour tissue by a pathologist (H.B.). DNA
was extracted from tumour cells and from normal mucosa
from two different blocks to avoid contamination. Purified
DNA was amplified by PCR, using the reference panel of
microsatellite primers recommended for colorectal cancer
by the National Cancer Institute which includes the markers
BAT25, BAT26, D5S346 (APC), D2S123 (-MSH2), and
D17S250 (p53). The presence of additional bands in the
PCR products from tumour DNA that were not observed in
DNA from corresponding normal tissue was scored as
unstable at that particular locus. Tumour samples were
classified as reflecting high-frequency microsatellite insta-
bility (MSI-H) when instability was observed for 2 or more
of the loci screened, low-frequency microsatellite insta-
bility when less than 2 of the loci screened were unstable,
or microsatellite stability, when stability was present at all
the loci tested.
MLH1 methylation analysis
Methylation was by Methylation-Sensitive Single-Strand
Conformation Analysis [30]. After deparaffinization and
staining in 0.1% toluidine blue, histologically selected
areas in tissue sections were manually microdissected.
Only the tumour cells were retained and final histological
control before collection of the tumour cells confirmed that
contamination with other cells was negligible. Extracted
DNA was modified with sodium bisulfite. A 178-bp frag-
ment of the MLH1 gene promoter was amplified by nested
PCR using the following primers: FW 50-GATTTTTTAAG
GTTAAGAG-30 and RV 50-ATAAAACCCTATACCTA
ATC-30 for the outer PCR and FW 50-TTTTTAGGAGTGA
AGGAG-30 and RV 50-AAACCCTATACCTAATCTAT
C-30 for the inner PCR amplification. The outer PCR
amplification was performed with 2 ll of modified DNA in
a total volume of 20 ll for 40 cycles. Twenty cycles were
performed for the inner PCR. Amplification products were
confirmed by visualization on a 2% agarose gel. Single-
strand conformation analysis was performed as previously
described [30]. The percentage of methylated alleles was
semiquantitatively estimated by comparing the intensity of
the methylated and unmethylated bands.
Detection of BRAF V600E mutation
Genomic DNA was extracted from fixed materials using
the DNeasy Tissue Kit (Qiagen, Hilden, Germany). DNA
was eluted with 60 lL of elution buffer and kept at -20C.
The most common T1799A transversion mutation (BRAF
V600E) was studied by direct sequencing after PCR
amplification of exon 15 of the BRAF gene. DNA was
amplified using the following primers: forward 50-TCTTC
ATAATGCTTGCTCTGATAG-30; reverse 50-TGGAAAA
ATAGCCTCAATTCTTAC-30. Sequencing with the inter-
nal primer 50-TCTACTGTTTTCCTTTACTTACT-30 was
performed colorimetrically using the BigDye Terminator
v3.1 Cycle Sequencing Kit on an ABI PRISM 3770 genetic
analyzer (AppliedBiosystems, Foster City, CA, USA).
Germline mutation analysis
Complete screening for both point mutations and gross
deletions in the MLH1gene (NM 251.2) was performed on
genomic DNA from each proband. Exons and adjacent
splice junctions were amplified by PCR and both DNA
strands were sequenced. To standardize bidirectional
sequencing, M13-21 and M13REV primers were added as
tails at either primer of the pair corresponding to a specific
exon. Genomic rearrangements, mostly as large deletions,
were searched for using multiplex ligation-dependent
probe amplification (MLPA, MRC-Holland). Mutation
nomenclature follows HGVS guidelines (www.hgvs.org)
with number one corresponding to ‘‘A’’ of the initiating
translation codon. The presence of a pathogenic germline
mutation in the proband was confirmed from a second
sample of peripheral blood.
Results
The results are summarised in Table 1. All cases (100%)
of sporadic MSI-H MLH1 silenced CRC were MLH1
methylated. Eight out of 11 cases carried the BRAF
mutation (73%) whereas 3 cases were BRAF wild type
(27%). In MLH1 mutated HNPCC patients, one case
showed MLH1 methylation (6%) and none of the cases was
BRAF mutated (0%). Sporadic MLH1 silenced CRC and
MLH1 mutated HNPCC were subdivided into 4 groups
according to their MLH1 et BRAF status: Group 1 of
sporadic CRC: 8/11 (73%) presented with BRAF mutation
and MLH1 methylation; Group 2 of sporadic CRC: 3/11
(27%) presented with BRAF wild type and MLH1 meth-
ylation; Group 3 of HNPCC: 15/16 (94%) harboured a
BRAF wild type and were MLH1 unmethylated; Goup 4 of
HNPCC: 1/16 (6%) were BRAF wild type and MLH1
methylated.
When we added all sporadic MLH1 silenced CRC and
MLH1 mutated Lynch syndrome we found that 4 cases
(15%) out of 27 MSI-H CRC presented with both BRAF
wild type and MLH1 methylation gene.
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Discussion
Germline mutations in mismatch repair (MMR) genes
affecting mainly MSH2 and MLH1 cause susceptibility to
Lynch syndrome or HNPCC, a dominant inherited disorder
accounting for approximately 2–5% of all cases of CRC [2,
31–33]. The identification of patients with a pathogenic
MMR mutation is a major issue because morbidity and
mortality from CRC can be reduced by early and intensive
screening [1, 18, 34–36]. However, the diagnosis of Lynch
syndrome is hampered by the lack of simple and specific
diagnostic criteria. Because MSI resulting from defective
MMR is a hallmark of tumours arising in the Lynch syn-
drome [1, 3], international criteria have been developed to
combine clinical and molecular features to help identify
patients at high risk of a diagnosis of Lynch syndrome [15].
Current recommendations include a prescreen phase by
analysis of tumours for the presence of MSI and the
absence of at least one MMR protein expression by
immunohistochemistry (IHC) [6, 37, 38]. Results from IHC
allow to target the relevant gene which needs to be
extensively analyzed. In this context, available data show
that an abnormal immunostaining of MSH2 and MSH6
proteins is most likely the result of germline mutations
[16, 17]. MSI-H CRC with loss of MLH1 protein are more
difficult to interpret and classify as MLH1 extinction is also
observed in approximately 10–15% of sporadic CRC, as a
result of epigenetic silencing of the MLH1 gene by meth-
ylation of the promoter region [8]. The aim of this study
was to evaluate strategy that would select more effectively
MLH1 mutated HNPCC patients. This is of major impor-
tance as the search for a causative germline mutation
remains the most time-consuming and expensive step of
the entire approach.
In a previously published study of a series of MSI-H
CRC patients, we proposed a cost effective and time saving
procedure for MLH1 mutated Lynch syndrome cases
detection algorithm [19]. Selection of MSI and IHC anal-
ysis represented the first step in Lynch syndrome detection
and in cases of abnormal expression of MLH1 protein, the
search for a MLH1 methylation represented the second
step. In the present study, we wished to improve the
selection of MLH1 mutated HNPCC patients by adding the
search for BRAF mutation, and this was evaluated in a
series of sporadic CRC negative for an MLH1 mutation and
familial HNPCC positive for an MLH1 mutation. In this
report, we examined the prevalence of MLH1 methylation
in MLH1 mutated HNPCC and sought to determine whe-
ther the presence of a MLH1 methylator phenotype is
informative to improve selection of true HNPCC patients.
Overall, there was significantly less MLH1 gene-promoter
methylation in HNPCC patients when compared with
sporadic cancers that were MSI-H. Only 6% of HNPCC
cases were methylated in the MLH1 promoter region,
compared to all MLH1 negative sporadic MSI-H cases.
At 100%, the level of MLH1 methylation in sporadic
tumours was consistent with previous findings [8, 21, 22,
39]. It has been suggested that HNPCC cancers, although
characterised by an MSI-H phenotype, show significantly
less methylation than their sporadic counterparts, and by
inference, are driven by an alternative mechanism acting as
the ‘second hit’ required to inactivate the wild-type allele
in HNPCC such as allelic loss [29, 40]. The important
variability of methylation levels reported to be associated
with MLH1 in Lynch syndrome is likely to reflect selection
of different CpG-rich regions of the promoter examined
between studies [24, 41].
Recently, an oncogenic V600E (previously known as
V599E) hotspot mutation in BRAF, a kinase encoding gene
from the RAS/RAF/MAPK pathway, has been found in
colorectal tumours that show MMR deficiency [25, 42, 43].
Moreover, it has been shown that these mutations occur
almost exclusively in tumours located in the proximal
colon and with hypermethylation of MLH1, the gene
involved in the initial steps of development of these
tumours [26, 28]. However, in more detailed analyses,
BRAF mutations were not detected in those cases with or
presumed to have a germline mutation in either MLH1 or
MSH2 [28, 44]. In a recent study, Loughrey et al. [45],
demonstrated the clinical validity and utility of V600E
mutation testing in a familial cancer clinic setting. Since
mutation in BRAF is present in the majority of tumours
with hypermethylation of the MLH1 promoter but not in
cases with germline MLH1 mutations, the combination of
microsatellite instability testing, MLH1 hypermethylation,
and BRAF (V600E) mutation analysis best distinguishes
sporadic CRC from Lynch syndrome. In our series reported
in the present report, we have shown that BRAF-V600E
mutation was absent in 100% of MLH1 mutated HNPCC,
and was detected in 73% of MSI-H MLH1 negative spo-
radic colorectal tumours, thus absent in 27% of this group.
In addition, our data indicated a significant correlation
Table 1 MLH1 methylation and BRAF mutation in sporadic MLH1 negative CRC and MLH1 mutated HNPCC cases
MLH metlylated MLH unmethylated BRAF mutated BRAF wild type
Sporadic CRC 11/11 (100%) 0/11 (0%) 8/11 (73%) 3/11 (27%)
HNPCC 1/16 (6%) 15/16 (94%) 0/16 (0%) 16/16 (100%)
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between a BRAF mutation and MLH1 methylation in spo-
radic MSI-H MLH1 negative CRC and a significant cor-
relation of a BRAF wild type and MLH1 unmethylation in
Lynch syndrome patients, as observed by others [29, 43,
46]. Overall, tumours that have the BRAF V600E mutation
and exhibit MLH1 promoter hypermethylation are almost
certainly sporadic, whereas tumours that show neither are
most likely inherited.
Although the above strategy allows to classify 85% of
MSI-H CRC into HNPCC and sporadic variants, HNPCC
cases with MLH1 methylation and sporadic CRC cases
without mutation of BRAF gene remain more difficult to
classify. Nevertheless, this group represented only 15% of
all MSI-H CRCs studied. This strategy has helped tight-
ening the analysis on a small group of cancers with unclear
genetic profile and for which a genetic counselling and
sequencing MLH1 mutation should be offered.
On the basis of our results we recommend the incor-
poration of BRAF V600E mutation and MLH1 methylation
testing into the laboratory algorithm for pre-screening
patients with suspected HNPCC, whose CRCs show loss of
expression of MLH1 protein. In summary, our data suggest
the following algorithm (Fig. 1): (1) no further molecular
analysis should be performed in cases of colorectal
tumours with MLH1 methylation and BRAF mutation and
these cases should be considered as sporadic CRC; (2)
colorectal tumours with unmethylated MLH1 and negative
for BRAF mutation should be considered as Lynch syn-
drome; (3) among CRC with MLH1 promoter methylation
but negative for BRAF mutation, only a subset of patients
are expected to be true Lynch syndrome. Genetic
counselling should be offered before searching for MLH1
gene mutations. The proposed algorithm allows to spare
time-consuming and costly efforts associated with unnec-
essary whole gene analysis.
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